SCHEMBL5259792

SCHEMBL5259792

Cc1cc(C)nc(Nc2ccc(-c3nc4ccccc4s3)c(O)c2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.58
RAB9A P51151 6/20 0.58
NPC1 O15118 5/20 0.58
KDM4E B2RXH2 4/20 0.58
NPSR1 Q6W5P4 1/20 0.58
SMN1; SMN2 Q16637 4/20 0.56
RXFP1 Q9HBX9 5/20 0.56
AURKB Q96GD4 2/20 0.55
EGFR P00533 1/20 0.55
KDR P35968 1/20 0.55
LMNA P02545 3/20 0.53
MEN1 O00255 6/20 0.53
KMT2A Q03164 6/20 0.53
POLB P06746 4/20 0.49
BLM P54132 1/20 0.49
PSMD14 O00487 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
TP53 P04637 3/20 0.48
GAA P10253 2/20 0.48
APP P05067 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5259019 0.92 MAPT (0.64) MAPTRAB9ANPC1KDM4ENPSR1
SCHEMBL2588882 0.85 MAPT (0.58) MAPTRAB9ANPC1KDM4ENPSR1
SCHEMBL12157481 0.85 MAPT (0.52) MAPTRAB9ANPC1KDM4ENPSR1
SCHEMBL5260103 0.85 EGFR (0.62) MAPTRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL5263632 0.82 APP (0.63) MAPTRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL15958900 0.82 MAPT (0.64) MAPTRAB9ANPC1KDM4ENPSR1
SCHEMBL13857587 0.82 MAPT (0.67) MAPTRAB9ANPC1KDM4ENPSR1
SCHEMBL5259397 0.80 SMN1; SMN2 (0.60) MAPTRAB9ANPC1KDM4ESMN1; SMN2
SCHEMBL2581070 0.80 AURKA (0.52) MAPTRAB9ANPC1KDM4ENPSR1
SCHEMBL12157485 0.79 MAPT (0.56) MAPTRAB9ANPC1KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007009524-A1 2-ARYLBENZOTHIAZOLES AND USES THEREOF 4SC AG (DE) 2007-01-25 WO disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof 4SC AG (DE) 2007-01-25 US disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed
EP-1746096-A1 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer 4SC AG (DE) 2007-01-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021446-A1 2-arylbenzothiazole analogues and uses thereof NR2E1, NR2E3, NR0B2 MAPT 4822/4885RAB9A 3722/4885NPC1 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.